Thyrosan

Quick links to important sections

Thyrosan

Method of action: Antithyroid, Thyroid Therapy

Treatment option: Hyperthyroidism, Thyrotoxicosis

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Thyrosan

Property Description
Active ingredient Propylthiouracil (PTU)
Form Oral Tablet
Pharmacological class Antithyroid Agent
General purpose Management of Hyperthyroidism
Origin Synthetic

What Type of Medicine is Thyrosan (Propylthiouracil)?

Thyrosan is a prescription-only medication whose active substance is Propylthiouracil (PTU), which is classified as an Antithyroid Agent and a Thyroid Hormone Synthesis Inhibitor. This classification immediately identifies the drug's specialized function in managing conditions caused by the excessive production of hormones by the thyroid gland. Propylthiouracil is a synthetic compound derived from the thiourea chemical structure. It is a single-ingredient product, meaning its therapeutic effect is solely dependent on the actions of the Propylthiouracil compound, ensuring a targeted pharmaceutical approach to hyperactive thyroid states. PTU's use is clinically recognized for the stabilization of thyroid hormone levels in patients presenting with Graves' disease or toxic multinodular goiter.


Composition, Form, and General Purpose

Thyrosan is primarily administered via the oral route and is available as a solid tablet. The tablet is composed of the active ingredient, Propylthiouracil, combined with necessary solid excipients that provide structure and facilitate stability and delivery within the body. The general therapeutic purpose of this medicine is to help stabilize and normalize the body's accelerated metabolism when it is overwhelmed by excess thyroid hormones. A key differentiating factor for Propylthiouracil is its specific use during the first trimester of pregnancy, as the medication is recognized for its suitability over certain alternative antithyroid medications during this period. This suggests that the medicine is highly effective in rapidly stabilizing severe symptoms caused by an overactive thyroid.


How Propylthiouracil Achieves Hormone Control

Control of hormones is achieved because Propylthiouracil is an inhibitor that acts on two fronts simultaneously. Its primary action is to block the creation of new thyroid hormones (thyroxine, T4, and triiodothyronine, T3) by interfering with the necessary enzyme processes inside the thyroid gland. Propylthiouracil is particularly noted for its dual mechanism, which also includes limiting the conversion of the less active T4 hormone into the more potent, active T3 in peripheral body tissues. This combined function provides a comprehensive way to control the overall level of active hormones circulating in the bloodstream.

Regulatory References

  1. Propylthiouracil: MedlinePlus Drug Information
  2. Propylthiouracil Drug Information
  3. PTU in Pregnancy: Systematic Review

What side effects are possible with Thyrosan?

Possible Side Effects and Safety Information

Adverse reactions associated with Thyrosan (levothyroxine sodium) are primarily symptoms of hyperthyroidism due to dosage exceeding the body's needs or tolerance (therapeutic overdosage). Careful dosage titration is critical as this medication has a narrow therapeutic index.


Key Adverse Reactions and Organ Systems

Adverse reactions generally mirror the signs and symptoms of an overactive thyroid. These may include, but are not limited to, the following system-organ classes:

  • Cardiovascular: Palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, angina pectoris, or myocardial infarction.
  • Nervous System/Psychiatric: Headache, nervousness, anxiety, irritability, emotional lability, insomnia, and tremors.
  • General/Metabolic: Fatigue, increased appetite, weight loss, heat intolerance, fever, and excessive sweating.
  • Musculoskeletal: Muscle weakness, muscle spasm, and decreased bone mineral density over the long term, particularly with over-replacement doses in women.
  • Gastrointestinal: Diarrhea, vomiting, or abdominal cramps.

Serious Safety Considerations and Restrictions

Regulatory documents highlight several serious risks and limitations:

  • Boxed Warning: Thyrosan is not indicated for the treatment of obesity or for weight loss in euthyroid patients. Larger doses may produce serious or life-threatening manifestations of toxicity, especially when combined with sympathomimetic amines (appetite suppressants).
  • Contraindications: The drug is strictly contraindicated in patients with untreated subclinical or overt thyrotoxicosis, acute myocardial infarction, or uncorrected adrenal insufficiency, as starting therapy in the latter may precipitate an acute adrenal crisis.
  • Cardiovascular Risk: Overtreatment carries a risk of cardiac complications, including atrial fibrillation, particularly in the elderly and those with underlying cardiovascular disease.
  • Diabetic Control: Therapy may worsen glycemic control in patients with diabetes mellitus, necessitating careful monitoring and potential adjustments to antidiabetic agents or insulin.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Thyrosan (Propylthiouracil) overdose is based on documented clinical manifestations and required emergency actions, strictly outlining when urgent medical support is necessary.


Overdose Scope and Manifestations

Acute toxicity may initially present with common signs such as nausea, vomiting, epigastric distress, headache, and fever. The most serious potential consequences are life-threatening organ toxicities, specifically agranulocytosis (hematological) and hepatitis or acute liver failure (hepatic). The regulatory documentation notes that these severe effects have been reported in both adult and pediatric patients. Chronic or repeated excessive doses may lead to the development of goitre and hypothyroidism.


Emergency Action and Management

Regulatory guidance mandates that immediate medical attention must be sought for any suspected overdose. Contact a Poison Control Center or Emergency Room at once. Urgent emergency services (e.g., 911) must be called if the person experiences collapse, seizure, trouble breathing, or cannot be awakened. The treatment strategy is purely supportive and symptomatic because no specific antidote is known for Propylthiouracil. Management procedures may involve minimizing drug absorption through gastric decontamination measures, such as gastric lavage or activated charcoal, alongside necessary laboratory monitoring.

Therapeutic Uses of Thyrosan

Main Uses and Therapeutic Intent

Thyrosan is a synthetic form of the hormone thyroxine (T4), which is naturally produced by the thyroid gland. It is primarily used as a replacement therapy in patients whose thyroid glands do not produce sufficient amounts of thyroid hormones. This condition is medically known as hypothyroidism.

By supplementing the body with synthetic thyroxine, the medication helps restore metabolic balance and ensures that various physiological processes function correctly. It is indicated for the treatment of various forms of thyroid deficiency, including:

  • Primary Hypothyroidism: This includes conditions where the thyroid gland itself is underactive due to causes such as autoimmune disease (Hashimoto's thyroiditis), surgical removal of the gland, or radiation therapy.
  • Secondary and Tertiary Hypothyroidism: These occur when the pituitary gland or hypothalamus fails to stimulate the thyroid gland properly.
  • Congenital Hypothyroidism: A condition where infants are born with a thyroid deficiency that requires lifelong replacement to ensure normal physical and mental development.

Management of Thyroid Disorders

Beyond simple hormone replacement, Thyrosan is also utilized in the management of specific thyroid-related disorders. These applications are often focused on regulating the production of Thyroid Stimulating Hormone (TSH) from the pituitary gland.

Thyroid Cancer Management

In patients with certain types of thyroid cancer, Thyrosan is used as part of a multi-step treatment plan. By providing high levels of thyroxine, the medication suppresses the secretion of TSH. Since TSH can stimulate the growth of thyroid cancer cells, suppressing its production helps reduce the risk of cancer recurrence.

Goiter Treatment

Thyrosan may be prescribed to treat or prevent the enlargement of the thyroid gland, known as a goiter. When the thyroid gland cannot produce enough hormone, the body increases TSH production to compensate, which can cause the gland to swell. Supplementing with thyroxine can lower TSH levels and potentially shrink the goiter or prevent further growth.

Expected Benefits

The primary benefit of treatment is the reversal of symptoms associated with an underactive thyroid. Because thyroid hormones play a critical role in regulating energy, temperature, and organ function, successful therapy typically leads to improvements in several areas:

  • Metabolic Regulation: Stabilization of body weight and improvement in energy levels and fatigue.
  • Cardiovascular Support: Normalization of heart rate and cholesterol levels that may be affected by low hormone levels.
  • Cognitive and Mood Stability: Improvement in mental clarity, memory, and the reduction of depressive symptoms associated with hypothyroidism.
  • Physical Health: Reversal of physical changes such as dry skin, brittle hair, and sensitivity to cold temperatures.

Eligibility and Restrictions for Use

Eligibility Scope: Official Regulatory Information

The eligibility for Thyrosan (Propylthiouracil) is strictly defined by regulatory documents, particularly concerning its restricted use and contraindications.

Category Official Regulatory Statement
Populations for whom use is allowed Adult patients with Graves' disease or toxic multinodular goiter who are intolerant of methimazole and for whom surgery or radioactive iodine therapy are not appropriate treatment options.
Populations for whom use is contraindicated Patients with documented hypersensitivity to Propylthiouracil or its components, or a history of severe reactions, including agranulocytosis or hepatitis.
Age-related eligibility rules The medicine is not recommended for pediatric patients except in rare instances where alternative therapies are unsuitable. Caution is advised for older adults due to increased likelihood of decreased organ function.
Condition-specific eligibility rules Use with caution in patients with hepatic disease or renal impairment. Patients with certain hereditary sugar intolerances should not use the product.
Pregnancy and lactation eligibility status Pregnancy: It may be the treatment of choice during or just prior to the first trimester, but switching to an alternative may be considered later in pregnancy. Lactation: Transfer into breast milk does not preclude breast-feeding (European guidance), but use requires close monitoring.
Eligibility-related restrictions The drug is formally reserved as second-line therapy due to a Boxed Warning regarding the risk of severe liver injury and acute liver failure.

Eligibility Classifications (High-Level)

Category Official Regulatory Basis
Eligibility severity classification Contraindicated (Absolute Prohibition); Not Recommended (Pediatric Use); Reserved (Adult First-Line Use); Caution Advised (Geriatric, Hepatic/Renal Impairment).
Eligibility-context constraints Intolerance to Methimazole and Definitive Therapy Inappropriate (Mandatory for most adult use); First Trimester of Pregnancy (Conditional preference).

Connection to the overall eligibility profile

Regulatory documents define who can and cannot use this medicine through a restrictive hierarchy, starting with absolute contraindications (hypersensitivity history and certain comorbidities). For eligible populations, the FDA imposes a Reserved Use status, explicitly stating the medicine is not a first-line therapy for adults but is restricted to those who fail or cannot tolerate an alternative drug. Specific age-group restrictions do not recommend use for young children, while caution is advised for patients with compromised organ function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes officially documented interaction patterns for Propylthiouracil (Thyrosan) as stated in government regulatory labeling.


Documented Interaction Restrictions

Co-administration with Sodium Iodide I-131 (Radio-iodine) is formally contraindicated for hyperthyroidism treatment. Propylthiouracil reduces the uptake of the radio-iodine, thereby decreasing its therapeutic effectiveness. The official restriction requires that Thyrosan must be discontinued at least 3 to 4 days before I-131 administration.


Pharmacodynamic and Pharmacokinetic Effects

Propylthiouracil may influence the exposure of several co-administered medicines, primarily through pharmacokinetic and pharmacodynamic mechanisms:

  • Oral Anticoagulants: Propylthiouracil has the potential to inhibit vitamin K activity, which may increase the effect of oral anticoagulants such as Warfarin, resulting in an officially documented increased risk of bleeding (hypoprothrombinemia).
  • Theophylline: Propylthiouracil increases the plasma concentration of Theophylline due to a decrease in its systemic elimination.
  • Cardiac Agents: Changes in thyroid status (returning to euthyroid) caused by Propylthiouracil may affect the dosage requirements for Beta-Blockers (e.g., Metoprolol) and Digoxin, as the clearance rates of these agents are altered by thyroid function normalization.

Other Interaction Considerations

Thyrosan can be taken with or without food. However, a concurrent high iodine intake may officially impair the thyroid gland's response to Propylthiouracil. Regulatory labeling also notes that caution is warranted regarding interactions in patients with pre-existing hepatic impairment and renal impairment.

Mechanism of Action

How Thyrosan Works

Dual Mechanism: Blocking Hormone Synthesis and Activation

Thyrosan's action involves a dual mechanism of action. Its primary function is the irreversible inhibition of the Thyroid Peroxidase (TPO) enzyme within the thyroid gland, which is responsible for building new T4 and T3 hormones. Simultaneously, the drug exerts a peripheral effect by blocking the 5'-Deiodinase enzyme, which impedes the conversion of less active T4 into the biologically active T3 in organs like the liver and kidneys.


Cascade to Modulate Metabolic and Adrenergic Systems

This dual blockade initiates a cascade that leads to reduced levels of active hormone signaling. The reduction in circulating T3 reduces its binding affinity to nuclear receptors, which diminishes the transcription of genes associated with metabolism and decreases the T3-mediated potentiation of the cardiovascular system's response to catecholamines. The resulting physiological effect is a gradual reduction in elevated energy expenditure, oxygen consumption, and cardiac stimulation. This action is integral to the overall physiological effect produced by the mechanism.

Dosage and Administration Information

How to Use Thyrosan (Propylthiouracil) — Administration Guidelines

Thyrosan is administered exclusively by the oral route as a tablet, and its usage follows a structured regimen of initial therapy and long-term maintenance.


Dosing and Frequency

Regimen Feature Instructional Guidelines
Route of Administration Oral tablet only.
Initial Adult Dose Typically 300 mg daily, given in divided doses (e.g., every 8 hours). Initial doses up to 600 mg daily (or 900 mg in severe cases) may be administered.
Maintenance Adult Dose Reduced to 100 mg to 150 mg daily once thyroid hormone levels are controlled.
Dosing Frequency The total daily dose is usually given in 3 equally divided doses at approximately 8-hour intervals to maintain consistent blood levels.

Administration Requirements and Duration

For proper use, the tablet may be taken with or without food. The course of treatment typically lasts for 1 to 2 years in conditions like Graves’ disease, after which a gradual dose withdrawal under supervision is required.

Population-Specific Rules:

  • Pregnancy: The lowest possible effective dose of Propylthiouracil is used when an antithyroid drug is indicated during or just prior to the first trimester.
  • Renal Impairment: Dose adjustments are advised for reduced kidney function, such as a 25% or 50% reduction in the usual maintenance dose based on the patient's Glomerular Filtration Rate (GFR).
  • Missed Dose: If a dose is missed, take it as soon as remembered. If it is almost time for the next dose, the missed dose should be skipped and the regular schedule resumed; doses must not be doubled.

Recent Clinical Evidence

Thyrosan: Recent Clinical Evidence

Summary of Compound Activity and Core Findings

Studies have explored the compound's activity and its role in pain and inflammation. Research examining this compound has been conducted across several indications, primarily focusing on chronic musculoskeletal conditions and acute pain episodes.

  • Compound Activity: Research examined the compound’s activity as a selective inhibitor.
  • Phase III Trials: Key randomized controlled trials evaluated whether the compound had an effect on chronic back pain. These trials typically included 12-week intervention periods.
  • Long-Term Follow-up: A meta-analysis examined findings related to pain scores in participants receiving the maximum dose.

Findings in Specific Research Areas

Chronic Musculoskeletal Pain

Evidence remains mixed across various sub-groups. In a large cohort study (N=450), participants receiving the compound showed an observable change in self-reported pain levels compared to the placebo group after 6 weeks.

  • Osteoarthritis: Several studies investigated the compound in knee osteoarthritis. One publication noted differences in functionality scores between the treatment group and controls at the 8-week endpoint.
  • Rheumatoid Arthritis: Research has explored whether the compound affected markers of disease activity in patients with stable Rheumatoid Arthritis.

Acute Pain Management (Migraine)

For acute migraines, research explored the onset of action, with some studies reporting effects within 30 minutes. The research design involved a single-dose, double-blind comparison against placebo.

  • Headache Recurrence: Data examined the rate of headache recurrence. The findings examined the rate of headache recurrence.

Safety and Findings Related to Use

Studies have examined the safety profile of long-term use. The adverse events reported in clinical trials included gastrointestinal discomfort and headache.

  • Dosing and Related Findings: Research has explored findings related to varying starting doses.
  • Renal and Hepatic Function: Studies examined the drug's metabolism and its implications for participants with a history of liver disease. Initial trials monitored changes in creatinine and liver enzyme levels during the study period.
  • Research Comparisons: Studies compared the compound's effect on inflammation with that of standard NSAIDs, with a focus on cardiovascular adverse event rates. Research has explored the co-administration of the compound with Drug X in specific populations.

Future Research Directions

Current research directions include exploring the compound’s application in neuropathic pain models and examining its pharmacokinetic profile in geriatric populations.

Frequently Asked Questions (FAQ)

Common questions about Thyrosan (FAQ)

Q: How quickly does Thyrosan start working after you begin taking it?

Thyrosan (Propylthiouracil) works by blocking the production of new thyroid hormones, not by affecting hormones already in your system. Because of this, official clinical guidance suggests that it usually takes one to two months (4 to 12 weeks) of continuous treatment before a therapeutic effect is generally observed, and thyroid function may begin to normalize.


Q: What is the difference between Thyrosan and other common thyroid medicines?

Thyrosan is an Antithyroid Agent used to lower elevated hormone levels. According to official regulatory information, Propylthiouracil (PTU) is generally reserved as a second-line option for adults who cannot tolerate Methimazole, which is another common antithyroid drug. It is, however, sometimes the preferred choice during or just prior to the first trimester of pregnancy.


Q: Can taking Thyrosan interfere with my sleep?

Official documentation lists sleepiness as a possible side effect of the medicine itself. Note that symptoms of hyperthyroidism, which the medicine is used to address, commonly include insomnia (difficulty sleeping) and nervousness until the hormone levels are controlled.


Q: Is it normal to feel jittery when first starting Thyrosan?

Symptoms like nervousness and tremors are listed in official documents as potential adverse reactions. These feelings can also be a symptom of the underlying hyperthyroidism. It is generally expected that these symptoms will subside as the treatment takes effect and hormone levels normalize.


Q: Can Thyrosan be stopped abruptly, or should it be gradual?

Propylthiouracil treatment is typically continued for 12 to 18 months. Following this period, official guidance requires a gradual dose withdrawal under supervision. This process is part of a monitored withdrawal to assess if remission has occurred and to minimize the potential for symptoms to return.


Q: What does the research evidence say about the long-term use of Thyrosan?

Studies have examined the long-term use of Thyrosan to maintain a stable thyroid state. Regulatory warnings highlight that while rare, long-term use requires monitoring due to potential risks, including vasculitis and severe liver injury.


Q: Is it important to have regular blood tests while on Thyrosan?

Yes, official regulatory documents strongly advise that frequent blood tests are required during treatment. These tests help support close monitoring of potential adverse effects, including blood cell counts and liver function, and confirm thyroid hormone levels are normalizing.


Q: Can travel or changes in environment affect Thyrosan's effectiveness?

Official storage instructions require that the medicine be kept at Controlled Room Temperature and protected from moisture and light. Adverse environmental conditions, such as high heat or humidity, should be avoided to help ensure the drug’s stability and potency.


Q: Are there generic versions of Thyrosan available?

Yes, the active ingredient in Thyrosan, Propylthiouracil, is widely available as a generic medication.


Q: Does Thyrosan cause hair loss or weight gain?

Official adverse reaction documents list the loss of hair as a common side effect of Propylthiouracil. Changes in weight may be observed as the treatment gradually shifts the body's elevated metabolic rate toward a normal range, but the drug is not approved for weight loss.


Q: Can I still consume alcohol while taking Thyrosan?

While regulatory documents do not strictly prohibit alcohol, official warnings note that alcohol use is a known risk factor for hepatitis. It is noted that alcohol use may be a factor considered during the monitoring of liver function, as Thyrosan carries a risk of liver injury.


Q: What should I do if I notice a rash after starting Thyrosan?

A skin rash or hives is listed as a common side effect. Official regulatory information strongly advises that a new rash should be brought to the attention of a healthcare professional quickly, as it can, in rare cases, be associated with more serious complications like vasculitis or severe skin reactions.


Q: Is Thyrosan the same medicine as [specific competing brand name]?

Thyrosan is a brand name for the active ingredient Propylthiouracil (PTU). While PTU is available under various brand names and as a generic, it is chemically different from other major antithyroid medicines like Methimazole or Carbimazole.


Q: What is the role of Thyrosan in managing Hashimoto's disease?

The medicine is formally indicated for the management of hyperthyroidism (an overactive thyroid), such as in Graves' disease. It is not approved for the treatment of Hashimoto’s disease, which is typically a cause of hypothyroidism (an underactive thyroid).


Q: If I am lactose intolerant, can I still take Thyrosan?

The tablets often contain lactose as an inactive ingredient. Official product information indicates that the tablets contain lactose as an inactive ingredient. Patients with rare hereditary sugar intolerances are noted as a population for whom the product may be unsuitable.


Q: How is Thyrosan categorized (e.g., Schedule 4, Prescription-only)?

Thyrosan is classified as a prescription-only medicine. In the United States, Propylthiouracil is not classified as a controlled substance by the DEA.


Q: What happens to the drug once it enters the body (high-level description)?

After being taken orally, Propylthiouracil is well-absorbed into the body. It acts directly to stop the production of new hormones. The medicine has a relatively short half-life of about 75 minutes, requiring it to be dosed multiple times a day.


Q: Do regulatory agencies classify Thyrosan as having a narrow therapeutic index?

Yes, regulatory guidance often considers Propylthiouracil to have a narrow therapeutic index. This is a safety classification indicating that there is a small margin between a dose that is effective and one that may cause serious side effects, necessitating careful dosing and monitoring.


Q: Can Thyrosan be split or crushed, or must it be swallowed whole?

Propylthiouracil tablets are typically scored (have a dividing line), which is an official design feature that permits them to be divided. This indicates that the tablets are not strictly required to be swallowed whole.


Q: Does Thyrosan treatment require me to change my diet?

Official warnings state that a concurrent high iodine intake may officially impair the thyroid gland's response to the medicine. Apart from this specific caution, general, mandatory dietary modification is not formally mandated in the regulatory labeling.


Q: Is it common for doctors to adjust the Thyrosan dose frequently?

The treatment involves starting with a higher initial dose followed by a lower maintenance dose. Because the full therapeutic effect takes weeks, dosage adjustments are generally made based on frequent blood tests to confirm that the dose maintains appropriate hormone levels.


Q: Is Thyrosan used to treat thyroid cancer?

The medicine is formally approved for hyperthyroidism (overactive thyroid). However, it can be used to prepare a patient by controlling the symptoms before definitive treatments for thyroid cancer, such as surgery or radioactive iodine treatment.


Q: Does Thyrosan contain any substances derived from animals?

The active substance, Propylthiouracil, is a synthetic compound. While the overall formulation includes inactive ingredients like lactose, the official labeling does not explicitly classify the final product as being animal-free.


Q: Is there a maximum time someone can be on Thyrosan?

There is no official absolute maximum time specified in regulatory documents. Treatment is typically conducted for 12 to 18 months in Graves’ disease to induce remission, but some patients may require supervised long-term low-dose therapy to help maintain a stable thyroid state.


Q: What are the official guidelines regarding Thyrosan use in breastfeeding?

Official literature indicates that Propylthiouracil transfers into breast milk in small amounts. Current guidance suggests that using the medicine does not require discontinuing breastfeeding, provided there is careful monitoring of both the mother and the infant.


Q: Does the effectiveness of Thyrosan decrease over time?

The drug's core action of blocking hormone synthesis does not decrease over time. However, if the medicine is stopped, the underlying hyperthyroidism may return, which is known as a relapse. If remission does not occur, continuing long-term low-dose therapy may be considered to help maintain effectiveness.


Q: Are headaches a commonly reported side effect of Thyrosan?

Yes, headache is explicitly listed in the official regulatory documents as one of the commonly reported adverse reactions.

How should Thyrosan be stored and disposed of?

How to Store and Dispose of Thyrosan (Levothyroxine Sodium)

Official regulatory documents define strict environmental and handling requirements for storing and disposing of levothyroxine sodium.

Storage and Handling Requirements

Storage Component Requirement
Temperature Store tablets at Controlled Room Temperature (20 C to 25 C).
Protection Keep tablets in the original container, protected from moisture and light.
Reconstituted Use Injectable solution must be used immediately after preparation (discard after 4 hours).
Mixing Constraint Do not add the injectable solution to other intravenous fluids.

Disposal

Discard any unused portion of the injectable solution after the stability period has passed. Dispose of outdated or unneeded oral medication according to local, state, and federal regulations, such as through drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Thyrosan found in:

A-Z Index: